Mr. Adrian Mendes reports

PERIMETER JOINS INDUSTRY RELATIONS COUNCIL OF THE AMERICAN SOCIETY OF BREAST SURGEONS

Perimeter Medical Imaging AI Inc. has joined the American Society of Breast Surgeons' (ASBrS) Industry Relations Council (IRC).

ASBrS is the primary leadership organization for general surgeons who treat patients with breast disease and is committed to continually improving the practice of breast surgery by serving as an advocate for surgeons who seek excellence in the care of breast patients. The ASBrS Industry Relations Council (IRC) comprises companies involved in the diagnosis, treatment and care of breast disease, and who would like to connect in a more significant way with key leaders in breast surgery.

"We welcome Perimeter as a member company of our IRC at a pivotal time for the field," said ASBrS president, Dr. Michael Berry. "While there have been many exciting advancements in breast care over the past few years, there is no question that programs that support optimal and cost-effective care for our patients is a priority for collaboration between industry and our organization."

"We are honoured to join other companies -- both established and emerging -- on the ASBrS IRC as we continue to gain commercial traction with our current S-Series OCT system, while, at the same time, work closely with the U.S. Food and Drug Administration as it reviews the PMA application for our next-generation AI-enabled B-Series OCT product," commented Adrian Mendes, Perimeter's chief executive officer. "We look forward to contributing through our membership and activities to help advance the study and practice of breast surgery."

About Perimeter Medical Imaging AI Inc.

Based in Toronto, Canada, and Dallas, Tex., Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultrahigh-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the United States, the company's Food and Drug Administration-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents the company's next-generation artificial intelligence technology that has recently been evaluated in a pivotal clinical trial, with support from a grant of up to $7.4-million (U.S.) awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol PINK is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation and reducing re-excision rates. The safety and effectiveness of these uses has not been established.

We seek Safe Harbor.